Isis is a small formulation company that serves the local pharmaceutical market. They do contract formulation of drug products that are suitable for clinical testing for small pharma companies that lack certain key resources in their chemistry departments.
Therefore, they are a small company working in a relatively new, niche market. Since their customers are almost entirely small pharmaceutical companies Isis is vulnerable to the same volatility that permeates the pharma market. I don’t know anyone at Isis so I wouldn’t be able to comment on their health overall.
The long and short: so long as there are a good number of local small pharma companies that need chemistry formulation Isis will be in business. But if the small pharma companies fold or get bought out by bigger companies then Isis loses customers and will find itself out of business.
